McGrath, Lindsay A, Ryan, David A, Warrier, Sunil K, Coupland, Sarah E 
ORCID: 0000-0002-1464-2069 and Glasson, William J
(2023)
Conjunctival Lymphoma.
EYE, 37 (5).
pp. 837-848.
Abstract
Lymphoma of the conjunctiva is an ocular malignancy derived from clonal proliferation of lymphocytes. The majority of conjunctival lymphoma is extranodal marginal zone B-Cell lymphoma (EMZL), however diffuse large B-cell (DLBCL), follicular (FL), mantle cell (MCL) and T- cell subtypes are also seen. Clinical manifestations are non-specific, but include unilateral or bilateral painless salmon-pink conjunctival lesions. Approaches to treatment have centered around local immunomodulation, often with Interferon-α2b or Rituximab (anti-CD20 monoclonal antibody) with or without radiation. Although conjunctival lymphoma is generally considered an indolent disease, recent advances in next-generation sequencing have improved clinicians' ability to predict future recurrence or systemic disease through assessment of cytogenic and molecular features. In this paper, we review the classification, clinical features, diagnostic techniques, and emerging strategies for management and prognostication of conjunctival lymphomas.
| Item Type: | Article |
|---|---|
| Uncontrolled Keywords: | Conjunctiva, Humans, Lymphoma, Eye Neoplasms, Conjunctival Neoplasms, Antineoplastic Agents, Lymphoma, B-Cell, Marginal Zone, Rituximab |
| Divisions: | Faculty of Health and Life Sciences Faculty of Health and Life Sciences > Institute of Systems, Molecular and Integrative Biology |
| Depositing User: | Symplectic Admin |
| Date Deposited: | 18 Oct 2022 13:41 |
| Last Modified: | 02 Jun 2023 08:59 |
| DOI: | 10.1038/s41433-022-02176-2 |
| Open Access URL: | https://www.nature.com/articles/s41433-022-02176-2 |
| Related URLs: | |
| URI: | https://livrepository.liverpool.ac.uk/id/eprint/3165598 |
Dimensions
Dimensions
